The evolution of automation in clinical biochemistry laboratories is unparalleled. No longer is it simply being used to assist the laboratory technologist in test performance, it now includes processing and transport of specimens, loading of specimens into automated analyzers, assessment of the results of the tests performed, and storage of specimens.
Clinical biochemistry testing is an integral part of laboratory analysis and often marks the first line of tests among a battery of examinations. The clinical biochemistry laboratory is generally with the largest volume of samples and different tests to be carried out. Therefore, this sector proves extremely important, regarding both financial matters, and quality and safety of the presented diagnosis, seen that the reported results are essential to indicate a patient’s state, helping medical decision-making, and therapeutic conduct. Considering the relevance of the obtained results, it is increasingly necessary to have timely and good-quality analysis performed and released in the laboratory reports. Continuously improved processes must be the main focus of any organization, as those initiatives ultimately aim at offering better products or services to their clients, fully meeting their needs and thus preserving and, if possible, improving the level of competitiveness of the enterprise in the market. In the field of medicine, more than trying to satisfy clients’ desires, one tries unceasingly to optimize processes, aiming at minimizing risks to patients’ lives. This attitude is materialized in the provision of consistent and reliable diagnostic information in the exact moments they are more necessary. Technological advances in the area of laboratory biochemistry allowed the evolution of several types of analysis equipment that conduct tests with diverse methods, being able to analyze a great deal of samples in a short period of time.
Laboratories are trying to differentiate themselves by offering specialized tests such as drug screenings, extended lipid profile, therapeutic drug monitoring, and entering into quality accreditations like NABL. The advent of computer- or microprocessor-based technology and software programming ushered in a new era for diagnostic testing—one that eventually led to automated environments enabling clinical biochemistry laboratories to perform fast, high-quality testing, and gain workflow efficiencies. A number of technological advancements have been introduced so far, including instruments dedicated to a single or dual test menu, such as the flame photometer, and the chloride/CO2 and glucose analyzers. With each new system generation, novel features have been introduced – such as closed tube sampling, automated maintenance processes, streamlined calibration, and internet-based remote diagnostics – all of which are intended to help laboratories better meet the needs of physicians and patients, while creating efficiencies, driving quality, lowering costs, and addressing fluctuations in the workforce. Emerging technological innovations in biosensors, lab-on-a-chip, and wearable devices are transforming the point-of-care (PoC) diagnostic market. As systems are becoming more sophisticated, integration, convenience, and application specificity have become critical factors. Analyzers now offer a growing number of automated features to enable their users to achieve optimal productivity. A buyer can choose from a wide array of systems that offer everything from intelligent sample management and remote system diagnostics to advanced features.
The biochemistry sector is one of the fastest moving sectors in Indian IVD industry. Currently, the biochemistry auto-analyzers are the backbone of major diagnostic chains in the country. Biochemistry analyzers are used in all types of laboratories, from small PoC to high-throughput clinical labs, to test for analytes such as proteins, enzymes, and electrolytes. Benchtop analyzers are the most common type, but compact bedside models, usually with fewer test options, and high-throughput floor-based units are also available. The biochemistry market in India is dominated by few major multinational companies. Manufacturers are developing analyzers with low volume reagent consumption. The new instruments are able to automate repetitive sample analysis steps that would have otherwise been done manually. Manufacturers are customizing analyzers for use in smaller laboratories, use in very high volume situations such as in a large hospital, or in the field. As software capabilities continue to develop, clinical biochemistry analyzers will be able to offer increased testing speed and degree of automation. Moreover, as a result of the convergence of system engineering, automation, and IT technology, a significant change has been brought in the market. Advances in clinical biochemistry analyzers will be concurrent with the development of new assays, further improving patient care. The need of the hour is to validate multiple biomarkers in the field of cancer diagnostics in order to bring the molecular testing in the ambit of biochemistry analyzers.
Indian market dynamics
In 2018, the Indian biochemistry instruments and reagents market is estimated at Rs 1742 crore, with reagents continuing to dominate at Rs 1450 crore, at an 83.24 percent market share.
The floor standing analyzers are estimated at Rs 85 crore and 1610 units; benchtop analyzers at Rs 82 crore and 1580 units; and semi-automated analyzers at Rs 125 crore and 15,100 units.
In 2018, the outbreak of dengue, jaundice, and malaria were controlled. The effect of demonetization had faded. The MNCs found it challenging to maintain their respective shares and the segment saw growth in the vicinity of 12 percent as against some of its counterpart segments in the diagnostics industry, which saw a 20-25 percent growth.
The size of the segment in 2018 has been calculated on assigning a monetary value to all the instruments installed, whether placed or sold. The ratio of sold to placed instruments depends on the strength of the brand, and the type and price points of instruments. Over the last couple of years, the traditional ratio of 40 percent sold to 60 percent procured has transitioned to 25 percent sold and 75 percent placed.
As Ayushman Bharat gets implemented over the next couple of years, given the limited funds available with the government, it is anticipated that the government will take a page from the private sector and push for the operating lease model, similar to the likes of Lal Pathlabs and Metropolis. Number of tests conducted is expected to be huge, and with the sample transport model already established, testing shall be done at centralized units. This consolidation will hurt the equipment industry. This will certainly be a change from the high-end integrated systems procured by the government currently.
Market – 2018*
|Roche and Siemens
|Beckman, Abbott, Mindray, OCD, and CPC
|Trivitron, Sysmex, Tulip, BioSystems, and Accurex (Dirui)
|*Vendors are placed in different tiers on the basis of contribution of estimated value of total instruments installed-sold and placed to the overall revenues of the Indian fully automatic biochemistry instruments market.
|Mindray, Robonik, and CPC
|Agappe, Accurex, Tulip, Microlab, Beacon, regional brands in North and West India
|*Vendors are placed in different tiers on the basis of their sales contribution to the overall revenues of the Indian semi-automatic biochemistry instruments market.
|Transasia, Roche, Siemens, OCD,
|Randox, Accurex, Agappe, DiaSys, and CPC
|BioSystems, Fuji, and local brands
|*Vendors are placed in different tiers on the basis of their sales contribution to the overall revenues of the Indian biochemistry reagents market.
|ADI Media Research
Roche showcases how labs are driving change across health networks at AACC 2018. Roche has launched the cobas c 513 analyzer at the American Association for Clinical Chemistry (AACC) Clinical Lab Expo held from July 29 to August 2, 2018 by showcasing how laboratories are driving change at integrated health networks by optimizing both lab operations and clinical decision-making processes. The cobas c 513 analyzer is a fully automated chemistry platform that raises the standard in HbA1c testing throughput. Today’s laboratories are faced with tremendous pressure to increase productivity and reduce costs, while striving to achieve accurate and reliable results to help improve patient outcomes and quality of care. Choosing the right partner to help overcome these challenges is vital to a lab’s success. No matter the size of the lab, or lab network, Roche offers a solution to ensure the clinical chemistry needs are met. Enabling the personalization and standardization of lab’s processes, Roche cobas c 513 analyzer helps to achieve consistent results quickly. In addition, the company provides an extensive and expanding test menu so the laboratories can help provide patients with the results they need, now and in the future.
Beckman Coulter launches DxC 700 AU to help streamline laboratory workflow with a 30 percent reduction of test-processing steps. Beckman Coulter in October 2018 launched its new DxC 700 AU chemistry analyzer that brings together the advanced capabilities of two successful Beckman Coulter products-the simple intuitive design of the DxC analyzer and the robust throughput, workhorse capabilities and proven uptime of the AU analyzer-into one standardized platform designed to meet the needs of mid- to high-volume clinical laboratories. The DxC 700 AU chemistry analyzer reduces the number of test-processing steps by 30 percent, streamlining workflow for laboratory professionals. The reduction in steps is the result of powerful operating software, an all-new design, and an intuitive user-interface that allow operators to spend less time on daily tasks and more time producing the quality results that empower better decision-making for better patient care. Along with its efficiency, the DxC 700 AU analyzer reduces total cost of ownership by using longer lasting and fewer consumables compared to other industry same-class systems. The system is further designed for time- and cost-savings superior uptime through the unique Beckman Coulter 3&60 concept that gives laboratory staff the ability to change out replacement parts in three steps, within 60 seconds, with no tools.
The global biochemistry analyzers market size was valued at USD 3.3 billion in 2018 and is expected to witness a robust CAGR of 5.4 percent from 2019–2026, according to Coherent Market Insight. Biochemistry analyzers market is expected to gain significant traction due to increasing usage of biochemistry analyzers in laboratories for diagnosis of increasing infectious diseases and rising prevalence of lifestyle diseases, such as, diabetes and cardiovascular disorders. According to the International Diabetes Federation, more than 10 percent of the world’s adult population or around 642 million people will have diabetes by 2040; such high prevalence is projected to be a key driver of the market. Furthermore, growth in aging population is boosting the market as elderly people are generally prone to infectious diseases and other disorders. High preference for automated analyzers among medical professionals and healthcare initiatives from government is further augmenting the growth of the global market.
PoC testing is a major trend in the biochemistry analyzers and in vitro diagnostics markets, as it supports patient-centered approaches and provides faster results. PoC testing enables rapid analysis of blood samples, with devices designed to address the challenges faced in the treatment and diagnosis of various chronic diseases. Moreover, the high cost of clinical diagnostic devices has increased the demand and adoption rate of PoC testing devices. The specimens can be studied using a unique barcode number when automated biochemistry analyzers are used. The results obtained can be automatically viewed in the laboratory information system. The systems provide good quality results and avoid pre and post analytical errors, thereby generating accurate results. It generates quicker reports, which helps in better disease management and patient outcomes, especially in critical cases. In vitro diagnostic manufacturers are developing analyzers with new capabilities and feature sets, including greater use of automation, increases from low- or medium-volume to high-volume devices, and upgraded technology to offer a wider array of tests and provide faster and more accurate results.
Manufacturers are developing biochemistry analyzers with multiplexing analyzers that include the feature of positive identification, which reduces the process of repeated pathogen testing. The industry is highly competitive in nature due to the presence of various local and international manufacturers. Major players are spending huge capital in product innovations, product/service extensions, and mergers and acquisitions, in order to dominate in the industry. Key players operating in the global biochemistry analyzers market include ELITechGroup, F. Hoffmann-La Roche, Beckman Coulter, Thermo Fisher Scientific, Alfa Wassermann, Ortho-Clinical Diagnostics, Randox Laboratories, Meril, Hologic, Abbott, Danaher Corporation, Accurex Biomedical, Siemens, and Horiba Medical. In order to gain competitive advantage in the industry, these players are adopting various growth strategies, such as, collaborations, agreements, partnerships, and new product launches.
Development of technologically advanced analyzers
The evolution of automation in clinical biochemistry laboratories has paralleled that in the manufacturing industry, progressing from ﬁxed automation, whereby an instrument performs a repetitive task by itself, to programmable automation, which allows the instrument to perform a variety of different tasks. Intelligent automation also has been introduced into some individual instruments to allow them to self-monitor and respond appropriately to changing conditions. The improved reproducibility gained by automation has led to a signiﬁcant improvement in the quality of laboratory tests. Many small laboratories now have consolidated into larger, more efﬁcient entities in response to market trends involving cost reduction. The drive to automate these mega-laboratories has led to new avenues in laboratory automation. No longer is automation simply being used to assist the laboratory technologist in test performance, it now includes processing and transport of specimens, loading of specimens into automated analyzers, assessment of the results of the tests performed, and storage of specimens.
Fully automated biochemistry analyzers can perform functions such as recognition of sample and reagent bottles, cap piercing, tube sampling, dilution, and automatic re-run, which reduces human effort and time, and require lesser volumes of reagent and sample. These analyzers aid scientists in measuring the concentration of any substance in a reaction mixture. Therefore, the implementation of automation in the analyzers is expected to contribute to reduced turnaround time (TAT) and increased throughput. Conventional biochemistry analyzers that are used for repetitive analysis require large amounts of reagents and time. However, technologically advanced analyzers are now capable of automating the process of repetitive sample analysis that were earlier done by lab technicians. Industry players are developing analyzers with feature of positive identification that decreases the process of repeated pathogen testing. This feature is important for samples with low volume such as neonatal units. Furthermore, integrated systems that combine immunochemistry and biochemistry tests are gaining huge attention as they increase the workflow efficiency by delivering fast TAT and high throughput. They also help in achieving increased instrument capacity by connecting different analyzer units with a single sample presentation mechanism.
Clinical biochemistry laboratories are under pressure to produce faster results and manage resources more efficiently. Increasing number of samples to be analyzed is increasing the demand for faster analytical methods that are capable of providing better information for decision-making. The need for automated analyzers for environmental and industrial samples has increased the research for new and cost-effective strategies of automation and control of analytical systems. The widespread availability of open-source hardware along with novel analytical methods have opened the possibility of implementing standalone automated analytical systems at low cost. Today technology is evolving from a hardware-based approach to a software-based approach. Highly advanced software are available for robotic operations with high throughput and support various automated operations like auto dilution, auto-rerun with dilution, reflex testing, sample transport management, and effective handling of samples and reagents, while maintaining the accuracy in volume measurement. Evolutions in software have opened pathways for automation, which heightens consistency and reduces operator error, and for fast and accurate analysis, predictive analytics, and data interpretation, which help to ensure the highest quality of results. The advancement in the software also allows easy operation and interfaces of the instruments to various connecting devices like mobile/personal computers that allow minimum human interference and records the results as it is so that there will be very less chance of manipulating the obtained results, thus increasing the test/report quality.
The advent of computer- or microprocessor-based technology and software programming ushered biochemistry laboratories into a new era for diagnostic testing enabling laboratories to operate with greater efficiency than ever before. Computers and microprocessor technology have also enabled the creation of smaller-footprint units that accommodate higher test volumes. Today’s consolidated systems typically perform hundreds of tests on one platform, whereas preceding systems required a number of dedicated instruments, each performing only a few selected tests. With advancement in the IT, most of the new generation systems are equipped with reagent and sample barcodes having HIS/LIS connectivity. By integrating the systems to the HIS/LIS interface, the analytical errors are reduced drastically. One of the new trends is remote diagnosis where the hardware is connected to the cloud based server and is checked for errors periodically. This new initiative from the hardware manufacturers is one of the key reasons for the minimal down time. Integration is playing an important role in IVD and the manufacturers are moving toward integrated systems to give complete solution to the customers. Usage of smart card based technology is another trend in the industry. Now more systems are coming up with smart card based calibration/programming where the cost of calibration is eluded.
For conventional systems with turnaround table for samples, new generation systems are coming up with rack sampling technology for ease of use. These systems allow the customer continuous loading of sample without any interruption of the process and thus helps to reduce the TAT of testing. Fluidics mechanisms and photometry modules are evolving to a new era with the ability to handle very low volume liquids. There is a huge reduction in the reagent volume requirement and now there are systems which can perform the tests with 80uL reagent, reducing the cost of testing drastically. Latex enhanced immunoturbidimetry based testing (LEIT) is becoming popular in the industry because of its specificity, sensitivity, and accuracy. These parameters are easily adaptable to the new generation clinical chemistry platforms and witnessed an exponential growth over the last three years. It is expected that more parameters are going to be introduced in the LEIT platform which can be performed in the clinical chemistry systems to make the diagnosis easy and affordable.
The challenges faced by today’s laboratories are multiple – high false positive ratio, the ongoing pressure for faster TAT, a sudden spike in the number of samples to be processed, and the list does not stop there. Clinical chemistry tests form a very important set of tests in a pathology laboratory; a tool that clinicians and patients alike depend on to pin down the symptoms for treatment and relief. However, it is this very set of tests that have come in question. First, what is the normal and acceptable range (upper and lower limits) of different biomarkers in a particular population has been debated in different scientific fora. A second problem which the doctors and technicians have to grapple with is the variability of test-results in itself; even a broadly similar set of instruments and methods can provide variable results. It is then a real challenge to the physician to decide whether the patient is suffering from a disease or something else, since other factors can also cause changes in test levels. Standardization and harmonization of clinical chemistry testing are therefore still a formidable challenge, due to the lack of proper reference intervals and sometimes due to standardized measurement procedures. Laboratory medicine community the world over has realized that variability in test results in different platforms can create a lot of confusion to clinicians and the general population; harmonization of procedures is therefore the need of the hour.
In today’s changing healthcare climate, laboratories around the world are challenged to elevate patient care and reduce operating costs at the same time. The low cost of ownership of analyzers helps laboratories to achieve their goals and manage resources effectively without compromising quality. While choosing the right instrument is important in ensuring successful laboratory operations, it is only part of the equation. Laboratories today are looking for knowledgeable partners to help them apply proven continuous improvement strategies—borrowed from the manufacturing industry—to healthcare. A partner who is able to offer a total laboratory solution beyond instrumentation placement can help the laboratory to achieve its patient care and operational efficiency goals. This includes supporting the use of the instruments, identifying opportunities for automation, detecting workflow gaps, and helping to create efficiencies in managing resources. The road map for laboratory medicine, therefore will involve strategies for harmonizing, communicating, and integrating with all stakeholders, like clinicians, diagnosticians, and IVD industry, in order to formulate guidelines for assisting in correct measurement, diagnosis, and management of diseases.
Manufacturers will work to meet the laboratory’s need to manage increasing workloads with decreasing resources, simplifying labor-intensive tasks that are still performed manually today. Software development initiatives will target workflow inefficiencies and results processing. Cloud-based systems and integrated networks will enable patient histories to be recorded and recalled, regardless of where testing is performed. In addition to this, manufacturers will continue the trend of downsizing units to reduce footprint, allowing more testing capabilities with smaller-sized machines. Future growth will build on this foundation, providing more capabilities in smaller-sized units. Instrumentation alone is only part of the equation. A strategic partnership can optimize laboratory performance, strengthening system advantages by integrating them into a total lab solution.
Diabetes – A Global Healthcare Challenge
National Sales Manager, Patient
Product Manager- Biochemistry,
Sysmex India Pvt. Ltd.
Diabetes is global burden, globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. This reflects an increase in associated risk factors such as being overweight or obese.
Type of diabetes
Type 1 diabetes or insulin-dependent diabetes – It is characterized by deficient insulin production in the body. The cause of type 1 diabetes is not known, and it is currently not preventable; Type 2 diabetes accounts for most people with diabetes around the world. Symptoms may be similar of type 1 diabetes but are often less marked or absent. People with IGT (impaired glucose tolerance) or IFG (impaired fasting glucose) are at increased risk of heart attacks and strokes; Gestational diabetes (GDM) is a temporary condition that occurs in pregnancy and carries long-term risk of type 2 diabetes
Current treatment of diabetes does not prevent all complications, but the progress of complications can be slowed by early interventions. A regular health check-up, GTT, blood glucose, urine-glucose, and HbA1c test can help in early diagnosis.
People with diabetes should have periodic, comprehensive eye examinations. Timely laser photocoagulation and good control of blood glucose can prevent or delay the onset of irreversible vision loss. Measurement of urine protein will reveal early kidney damage, and the progression to kidney failure can be slowed by essential drugs routinely used to treat hypertension. Kidney failure is treated by dialysis or a kidney transplant. Proper footwear and regular examination of feet for signs of neuropathy, impaired blood flow, and skin changes can prevent foot ulcers that often lead to gangrene and limb amputation: interventions to promote and support healthy lifestyles, including healthy diet, physical activity, avoidance of tobacco use, and harmful use of alcohol; medication for blood glucose control – insulin or oral hypoglycaemic agents as required; medication to control cardiovascular disease risk; regular exams for early detection of complications: comprehensive eye examination measurement of urine protein, and assessment of feet for signs of neuropathy; and standard criteria for referral of patients from primary care to secondary or tertiary care.
India IVD Market – Factors and Emerging Trends
Advances in medical laboratory science technology have occurred rapidly and are projected to continue developing at a similar rate. This remarkable growth can be attributed to increased healthcare awareness, desire to undergo preventive health check Ups, availability of disease specific tests, corporate setups promoting health focus of employees, and drift from manual to semi-automated and automated equipment. Emergence of new concepts like point of care testing, near patient testing, increased automation, hospital laboratory management and customer relationship management have revolutionized this segment and contributed towards providing accurate and precise diagnosis at much faster rates. The new labs, with stringent budgets in smaller towns are opting for semi auto instruments, as the number of tests conducted also does not justify large initial investment. More than 4000 different diagnostic tests are now possible, and as more IVD tests become compatible with point-of-care (PoC) environments.
Healthcare industry is exploring numerous options to engage and render the service to its customers on online platform. Booking for laboratory tests from home, home collection of samples, digitizing records, improved turnaround time are some of the major emerging trends in the lab and diagnostic domain.
Few emerging trends that are transforming the industry
Preventive healthcare. With the raising awareness and an inclination to monitor health, considering the modern lifestyle we lead, people no longer wait for the symptoms to manifest and are happy to undergo periodic preventive healthcare check-ups to detect signs early, take the necessary precaution and prevent themselves from picking up diseases.
Unifying the fragmented diagnostic domain. The laboratories are now aiming for certification and accreditations. As laboratories are now focusing on quality and expanding their brand, the trend has bought down the cost to a certain extent and the services will get cheaper with continued unification of the industry.
Digital health records. Digitization of health records ensure that all laboratory reports are documented electronically and can be accessed virtually from anywhere and anytime.
Customer-centric approach. Laboratories are now offering customer centric health services without the prescription from a doctor. Diagnostic centers are also slowly transforming themselves into healthcare centers by extending their services to specialist consultations, surgical referrals and second opinions.
BioSystems Diagnostics, specializes in providing the full spectrum of clinical chemistry reagents and instruments to deliver quicker and accurate results for its customers and developing new markers with innovative technology by maintaining global standards of quality and excellence.
Immunoturbidimetric Reagents-Accurate Measurements Of Specific Proteins
Dr Rajesh Rengarajan
Product Manager-Clinical Chemistry
DiaSys Diagnostic India Pvt. Ltd.
Specific protein testing are important markers for various diseases for example microbial infections, cardiac risk, inflammatory response and even cancer. The measurement of proteins in the blood assists in the evaluation and diagnosis of various conditions.
Specific protein testing market: Drives and restrains
The specific protein testing market is anticipated to grow in coming years with the increasing geriatric population. Among all protein testing methods, specific protein testing has gained significant amount recognition in recent times. These kind of testing helps in the diagnosis of various health disorders including immune system disorder, such as rheumatoid arthritis. The effectiveness of the testing outcome is the major driver for the global specific protein testing market. The specific protein testing is an in vitro testing procedure that offers benefit to the specific protein testing market over the globe.
The measurement of protein concentration in plasma such as the activity of enzymes, the amount of transport proteins, hormones, cytokines, clotting factors, and complement proteins has proved useful in the diagnosis and management of various diseases. There are a variety of analytes generally classified as specific proteins that have wide ranging clinical utility. In the past, specific proteins were analyzed using radial immunodiffusion, immunoelectrophoresis and dedicated immunonephelometric or immunoturbidimetric methods.
Automation of specific protein testing offers rapid analysis, random access, high volume testing, and cost reduction. Shifting of specific protein analysis to a clinical chemistry platform result in reduced turnaround time for these tests and can allow for consolidation of testing and elimination of more specialized individual analyzers.
DiaSys diagnostic systems immunoturbidimetric test portfolio offers more than 20 ready-to-use, stability optimized reagents for routine and special diagnostics with outstanding performance. DiaSys immunoturbidimetric tests are available in different kit sizes for manual and automated use in various common clinical chemistry analyzers. Current portfolio of DiaSys immunoturbidimetric tests is available as open kits and system kits on respons 910 – Dedicated immunoturbidimetry analyzer.
Automation In Biochemistry Brings In Efficiency Of Testing
Product Manager – Biochemistry
Transasia Bio-Medicals Ltd.
Over the last 5 years, the biochemistry market has shown a steady growth due to implementation of advanced techniques, shift toward automation, advent of unique parameters, and comprehensive testing solutions that facilitate efficient, accurate outputs to obtain better clinical outcomes.
Clinical and technology trends
The market is experiencing a growing preference for fully automated analyzers, for the multitude of benefits they offer – convenience, flexibility in operations, less turn-around time, improved performance and quality, and increased profitability. However, laboratories are under increasing pressure for better clinical outcomes and to contain costs. In order to cater to these demands, manufacturers are incorporating certain advanced features such as static photometry technology, low reagent consumption, permanent hard glass cuvettes that are cost effective, on-board cooling, on-board laundry etc. that add to the efficiency of a fully automated analyzer.
Accreditation from reputed institutes further validates the quality of the automated system and reagents.
Automation is proving to be the biggest growth driver for this segment. Additionally, automation is enabling healthcare companies to meet regulatory compliance and data consolidation. Most of the latest systems are equipped with a reagent and sample barcode reader having HIS / LIS connectivity. Integrating the systems to the HIS/LIS interface has drastically reduced analytical errors. Internet-of-things (IoT) is turning out to be a game-changer for the industry. Automation combined with cloud-based technology is helping laboratories streamline daily operations, troubleshoot, and better manage patient information.
India’s leading IVD company, Transasia Bio-Medicals Ltd., is a pioneer in manufacturing biochemistry analyzers in India. It offers end-to- end solutions with its wide product range that includes semi and fully automated analyzers, reagents, and quality controls. In recent times, EM 200, a fully automated biochemistry analyzer has become an undisputed leader in mid-size segments with 5000+ installations and excellent service, back-up, and support.
Modern Trends In Clinical Chemistry
Rudra Prasad Chakraborty
Product Manager- Biochemistry, IVD,
Mindray Medical India Pvt. Ltd.
Clinical chemistry, also known as chemical pathology, clinical biochemistry, or medical biochemistry, is the area of clinical pathology or laboratory testing that is generally concerned with analysis of bodily fluids for diagnostic and therapeutic purposes. All biochemical tests come under chemical pathology. These are performed on any kind of body fluid, but mostly on blood. The common specimens tested in clinical chemistry are blood (serum or plasma) and urine. Many different tests exist to test for almost any type of chemical component in blood or urine. Components may include blood glucose, electrolytes, enzymes, hormones, lipids (fats), other metabolic substances, proteins, drugs etc.
Clinical chemistry tests are the most common and powerful diagnostic tool for clinicians for taking any decision regarding the treatment of patients. A modern state-of-the-art laboratory consists of full automated analyzers and/or total laboratory automations supported by strong IT tools to provide faster turnaround time with large numbers of tests. Trends in diagnostic industry are toward automation and an increasing practice of employing full automated systems in the laboratory is being seen. Also, trends toward use of close systems (instruments, reagents, and consumables from single vendor/manufacturer) in mid-size to large laboratory set-ups are putting complete solution providers in driver seat in the in vitro diagnostic (IVD) market.
Developments in assay technology consist of superior enzymatic methods, grating based optical systems, chemi-luminescence methods and integration of routine chemistry system with immuno-chemistry system. Also, developments on different bio-markers like NT-Pro BNP, enzymatic FPOX based HbA1c, sepsis related complications early-markers are providing better diagnostic eye to clinicians to manage critical patient situations.
Being a leading manufacturer of instruments and reagents, Mindray is passionate to impart the marvel of research in the IVD fraternity. Mindray produces a large array of instruments from entry level full auto to high end modular/integrated systems with the support of reagent/consumables to assure quality of diagnosis. Firmly committed to our mission of advancing medical technologies to make healthcare more accessible, we are dedicated to innovation in the fields of patient monitoring and life support, IVD, and medical imaging systems.